Market Analysis

Market Analysis

Dementia is a general term that describes a group of symptoms-such as decline in mental capability, judgment, language, complex motor skills, and other intellectual function-caused by brain damage from cerebrovascular, death of the brain's nerve cells, or neurons. Dementia may be caused by a number of factors, such as drug abuse, alcoholism, brain injury, side effects to certain medications, thyroid function abnormalities, vitamin B12 deficiency, etc.

Dementia including Alzheimer’s disease, is one of the biggest global public health challenges and disorder facing our generation. Vascular dementia is the second most common cause of dementia caused by brain damage.

From recent reports, markets for Alzheimer’s treatments exist with the development of some therapeutic methods and the increasing incidence of the disease. The increasing incidence of Alzheimer’s disease is mainly attributed to the growing number of people over the age of 65. Although some instances of young-onset have occurred, this is defined as Alzheimer’s symptoms in people under the age of 65. Alzheimer’s disease is estimated to affect up to 6% of the population over 65.

The global report for Alzheimer’s disease reached $10.2 billion in 2012 and still increasing. The global market for AD therapeutics and diagnostics by region should reach over $6.2 billion by 2020 from $4.4 billion in 2015, at a compound annual growth rate (CAGR) of 7.1% from 2015 to 2020.

Analyses of global market trends, with data from 2014, 2015 and 2016, and projections of CAGRs through 2021 has covered different types of tests, including esoteric, public health, anatomic technology, genomic testing, mass spectrophotometry, and other new technologies.

From an overview of the global market for laboratory-developed testing found that laboratory tests reached nearly $9.7 billion in 2015. This market is expected to increase from nearly $11.0 billion in 2016 to $14.9 billion in 2021 at a compound annual growth rate (CAGR) of 6.3% for 2016-2021.